A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC

Introduction: Evidence supports the addition of immunotherapy to definitive chemoradiation for unresectable stage IIIA NSCLC. Adding pembrolizumab to neoadjuvant chemoradiation in patients with resectable stage IIIA NSCLC requires study for safety and feasibility. Methods: Patients with resectable s...

Full description

Bibliographic Details
Main Authors: Christopher A. Lemmon, MD, Gregory M.M. Videtic, MDCM, Sudish Murthy, MD, PhD, Kevin L. Stephans, MD, Marc Shapiro, MD, Usman Ahmad, MD, Daniel Raymond, MD, Vamsidhar Velcheti, MD, Alejandro Bribriesco, MD, Xuefei Jia, MS, James Stevenson, MD, Nathan A. Pennell, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-07-01
Series:JTO Clinical and Research Reports
Subjects:
Neoadjuvant
Chemoradiation
Immunotherapy
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322000832

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322000832

Similar Items